Pediatrix Medical Group, INC 8-K filings

Pediatrix Medical Group announced robust second quarter 2026 financial results, exceeding prior year performance with increased net revenue and improved adjusted EBITDA.

Pediatrix Medical Group, Inc. reports on the departure of its Executive Vice President, General Counsel, Chief Administrative Officer and Secretary, Mary Ann E. Moore, and the appointment of David Haddock as the new General Counsel and Secretary.

Pediatrix Medical Group provided a second quarter update, confirming a stable payor mix and reaffirming its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million.

Pediatrix Medical Group shareholders approved an amended incentive compensation plan, increasing available shares and ratifying auditor appointment at the 2026 Annual Meeting.

Pediatrix Medical Group reported strong first-quarter results, exceeding expectations with net revenue of $476 million and Adjusted EBITDA of $58 million, driven by improved reimbursement and strategic acquisitions.

Pediatrix Medical Group announced fourth-quarter and full-year 2025 results, reporting Adjusted EPS of $0.50 for Q4 and providing a preliminary 2026 Adjusted EBITDA outlook.

Pediatrix Medical Group reported strong third-quarter results, exceeding expectations and raising its full-year 2025 Adjusted EBITDA outlook.

Pediatrix Medical Group's Board of Directors has authorized a new share repurchase program of up to $250 million of its common stock.

Pediatrix Medical Group reported strong second-quarter 2025 earnings, exceeding forecasts and raising its full-year Adjusted EBITDA outlook.

Pediatrix Medical Group, Inc. announced the appointment of Dr. Kurt Newman, former President and CEO of Children's National Hospital, as an independent director to its Board of Directors, effective July 1, 2025.

Pediatrix Medical Group held its 2025 Annual Shareholders Meeting on May 8, 2025, with all proposals passing including the election of directors, ratification of the auditor, and approval of executive compensation.

Pediatrix Medical Group reports a strong first quarter with increased earnings and raises its full-year Adjusted EBITDA outlook.

Pediatrix Medical Group's subsidiary, PMG Services, has amended and expanded its services agreement with Guidehouse Managed Services, extending the current term and establishing a new statement of work for services commencing July 1, 2025.

Pediatrix Medical Group announces Q4 2024 earnings of $0.36 per share, with adjusted EPS at $0.51, driven by top-line outperformance and completed portfolio restructuring.

Mark Ordan, previously Executive Chair, returns as CEO of Pediatrix Medical Group, succeeding James Swift, effective January 12, 2025.

Pediatrix Medical Group appoints Mark S. Ordan as CEO, succeeding Dr. James D. Swift, and anticipates achieving the high end or exceeding its previously issued adjusted EBITDA guidance for 2024.

Pediatrix Medical Group, Inc. has announced that Dr. Curtis B. Pickert will transition from his role as Executive Vice President and Chief Physician Executive, effective January 31, 2025.

Pediatrix Medical Group reported third-quarter earnings that modestly exceeded expectations, driven by strong same-unit revenue growth and progress in portfolio management.

Pediatrix Medical Group reported a net loss of $1.84 per share for the second quarter of 2024, alongside strategic portfolio management plans and executive leadership transitions.

Pediatrix Medical Group is eliminating the role of Executive Vice President, National and Market Operations, as part of its ongoing focus on operational efficiency.

Pediatrix Medical Group is focusing on operational efficiency, exiting certain business lines, and reaffirming its 2024 adjusted EBITDA guidance.

Pediatrix Medical Group held its 2024 Annual Shareholders Meeting, where all director nominees were elected, the appointment of PricewaterhouseCoopers LLP was ratified, and executive compensation was approved on an advisory basis.

Pediatrix Medical Group announced first quarter earnings of $0.05 per share, with adjusted EPS at $0.20, amidst ongoing restructuring efforts and a focus on operational efficiency.

Pediatrix Medical Group has signed an eight-year agreement with Guidehouse for enterprise revenue cycle management services.

Pediatrix Medical Group reported a loss of $1.50 per share for the fourth quarter of 2023, despite a slight increase in full-year revenue and a stronger cash position.